Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             167 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Author index 2005
 14 S1 p. S53-S56
4 p.
 artikel
2 Opening address/award lecture 2005
 14 S1 p. S1-
1 p.
 artikel
3 P96 Abstract withdrawn 2005
 14 S1 p. S42-
1 p.
 artikel
4 P16 Accessory breast carcinoma: a case report and review of the literature Lee, H.S.
 2005
 14 S1 p. S19-
1 p.
 artikel
5 P37 A comparative study of cyclooxygenase-2 expression in Korean and Caucasian patients with early-onset breast carcinoma Choi, D.H.
 2005
 14 S1 p. S26-
1 p.
 artikel
6 P87 Adriamycin Based Therapy Followed by Weekly Taxolas Neoadjuvant Treatment in Localised Breast Cancer Leviov, M.
 2005
 14 S1 p. S40-
1 p.
 artikel
7 P115 Age as a prognostic factor in postmenopausal breast cancer H bert-Croteau, N.
 2005
 14 S1 p. S47-
1 p.
 artikel
8 P29 Age does affect the HER-2/neu status of breast cancers Neven, P.
 2005
 14 S1 p. S24-
1 p.
 artikel
9 P12 Analysis of 25-hydroxyvitamin d3-1a-hydroxylase in normal and malignant breast tissue Friedrich, M.
 2005
 14 S1 p. S17-S18
2 p.
 artikel
10 P106 A Number-Needed-to-Treat(NNT) analysis of bonerelapse and mortality in a randomized trial of oral clodronate as supplementary adjuvant therapy for operable breast cancer Powles, T.
 2005
 14 S1 p. S45-
1 p.
 artikel
11 P94 A phase II study of neoadjuvant docetaxel plus doxorubicin in stage II, III breast cancer: A preliminary report (KBCS-01) Kim, S.
 2005
 14 S1 p. S42-
1 p.
 artikel
12 P60 A prospective trial of intraoperative radiotherapy for breast cancer Joseph, D.
 2005
 14 S1 p. S31-
1 p.
 artikel
13 P20 Assessment of breast cancer tumor size depends onmethod, histopathology and tumor size itself Fasching, P.A.
 2005
 14 S1 p. S19-S20
2 p.
 artikel
14 P43 Assessment of the Prognostic Value of HER2 ReceptorExpression in patients Treated for Breast Carcinoma Grzybowska-Szatkowska, L.
 2005
 14 S1 p. S27-
1 p.
 artikel
15 P51 Axillary lymph node ratio and total number ofremoved lymph nodes Lass, H.
 2005
 14 S1 p. S29-S30
2 p.
 artikel
16 P81 Benefits of switching postmenopausal women withhormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial Kaufmann, M.
 2005
 14 S1 p. S38-
1 p.
 artikel
17 P101 Brain as a sanctuary site for early relapse inpatientswith advanced breast cancer treated with trastuzumab Yau, T.
 2005
 14 S1 p. S43-
1 p.
 artikel
18 P28 Breast cancer characteristics in very youngpremenopausal, high-risk women, aged up to 35 Neskovic-Konstantinovic, Z.
 2005
 14 S1 p. S24-
1 p.
 artikel
19 P116 Breast cancer in elderly population aged 75 years ormore Sklar, Z.
 2005
 14 S1 p. S47-S48
2 p.
 artikel
20 P33 Breast Cancer in Women with Recent Exposure to Fertility Medications is Associated with Poor Prognostic Features Siegelmann-Danieli, N.
 2005
 14 S1 p. S25-
1 p.
 artikel
21 P118 Breast cancer mortality trends among white andblack women in the United States: an age-period-cohort analysis Jatoi, I.
 2005
 14 S1 p. S48-
1 p.
 artikel
22 P124 Breast cancer profile in Eastern Libya El Mistiri, M.
 2005
 14 S1 p. S49-S50
2 p.
 artikel
23 P22 Breast cancer screening of Korean women Hur, M.
 2005
 14 S1 p. S20-
1 p.
 artikel
24 P117 Breast carcinoma —B iologic factors and treatment approach in age groups population Rabkin, A.
 2005
 14 S1 p. S48-
1 p.
 artikel
25 P47 Breast conservation treatment in women with locallyadvanced breast cancer Parmar, V.
 2005
 14 S1 p. S28-S29
2 p.
 artikel
26 P113 Cancer guidelines: An Initiative of the Program inEvidence-Based Care (PEBC), Breast Cancer Disease Site Group (BCDSG) at Cancer Care Ontario (CCO) Trudeau, M.
 2005
 14 S1 p. S47-
1 p.
 artikel
27 P10 Can CISH bean alternative to FISH in the HER2/neu testing algorithm? Hanna, W.
 2005
 14 S1 p. S17-
1 p.
 artikel
28 P102 Cellular immunotherapy in late stage breast cancerpatients with reactivated autologous Memory T-cells derived from bone marrow Schuetz, F.
 2005
 14 S1 p. S43-
1 p.
 artikel
29 P119 Characteristics and outcome of breast cancer in patients <35 years old Gaki, V.
 2005
 14 S1 p. S48-
1 p.
 artikel
30 P58 Clinical treatment decision on local therapy inductal carcinoma in situ Steiner, M.
 2005
 14 S1 p. S31-
1 p.
 artikel
31 P32 Clodronate influence on the prediction ofchemotherapy effectiveness in patients with primary breast cancer Ivanov, S.D.
 2005
 14 S1 p. S25-
1 p.
 artikel
32 P1 Comparative study for the determination of HER2 geneamplification and overexpression in breast cancer Lee, Y.H.
 2005
 14 S1 p. S15-
1 p.
 artikel
33 P17 Comparison between the 5th and 6th American JointCommittee on Cancer (AJCC) staging system in 1,275 breast cancer patients Kang, S.H.
 2005
 14 S1 p. S19-
1 p.
 artikel
34 P104 Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases Zheng, M.
 2005
 14 S1 p. S44-
1 p.
 artikel
35 P109 Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases Kohno, N.
 2005
 14 S1 p. S45-S46
2 p.
 artikel
36 P5 Cpg island promoter hypermethylation in breast cancer development and progression Parrella, P.
 2005
 14 S1 p. S16-
1 p.
 artikel
37 P75 Current status and results of the second toxicityanalysis of a WSG/AGO-Mamma Intergroup Phase III trial AM02 “Ec->Doc” for patients with primary breast cancer and 1-3 positive axillary lymph nodes Schuett, G.J.
 2005
 14 S1 p. S37-
1 p.
 artikel
38 P38 Detection of angiogenic micrometastases in the drainage vein of breast by using RT PCR Saito, M.
 2005
 14 S1 p. S26-
1 p.
 artikel
39 P18 Development of the Breast Cancer ProfileChipTM, anew diagnostic device dedicated to breast cancer Borie, N.
 2005
 14 S1 p. S19-
1 p.
 artikel
40 P85 Direct comparison of primary (neoadjuvant) endocrine therapy vs primary chemotherapy in postmenopausal women with ER-positive breast cancer Semiglazov, V.
 2005
 14 S1 p. S39-
1 p.
 artikel
41 P89 Docetaxel/capecitabine (TX) vs.doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC): interim analysis findings from a phase III randomised trial Ro, J.
 2005
 14 S1 p. S40-
1 p.
 artikel
42 P92 Docetaxel versus epirubicin/cyclophosphamide (EC)as first-line therapy in metastatic breast cancer (MBC): results from the randomized phase II TIPP study Friedrich, M.
 2005
 14 S1 p. S41-
1 p.
 artikel
43 P31 Does HER2/neu expression on the primary tumor of breast cancer patients predict the phenotype of minimal residual disease? Rack, B.
 2005
 14 S1 p. S24-S25
2 p.
 artikel
44 P129 Early detection of breast cancer in core biopsies bymeans of quantitative RT PCR Vuaroqueaux, V.
 2005
 14 S1 p. S51-
1 p.
 artikel
45 P68 ECOG stage influences the choice of adjuvant therapy independently of ER status in surgically resected breast cancer (BC) patients (PTS). Results of the NORA study Cazzaniga, M.E.
 2005
 14 S1 p. S35-
1 p.
 artikel
46 P127 Efficacy data from the ATAC (“arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment Howell, Tony
 2005
 14 S1 p. S51-
1 p.
 artikel
47 P111 Efficacy of questionnaires related to psychosocialaspects of breast cancer in a multidisciplinary breast unit: Preliminary results Pruyt, M.
 2005
 14 S1 p. S46-
1 p.
 artikel
48 P120 Ethnic differences in patients presenting at a more advanced stage of breast cancer in Singapore — a single institution experience Ang, P.
 2005
 14 S1 p. S49-
1 p.
 artikel
49 P4 Evaluation of Msh2, MIh1, Brca1 and Fhit proteinexpression in T1 NO MO breast cancer Giarnieril, E.
 2005
 14 S1 p. S15-S16
2 p.
 artikel
50 P8 Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas Francis, G.
 2005
 14 S1 p. S16-S17
2 p.
 artikel
51 P11 Expression of ALCAM/CD166 and related proteins inbreast cancer: tissue and cell lines Jezierska, A.
 2005
 14 S1 p. S17-
1 p.
 artikel
52 P7 Expression of estrogen receptors alfa and beta andprogesterone receptor in invasive ductal and lobular breast cancer Litwiniuk, M.
 2005
 14 S1 p. S16-
1 p.
 artikel
53 P3 Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas Kov cs, A.
 2005
 14 S1 p. S15-
1 p.
 artikel
54 P63 Feasibility of concurrent adjuvant chemotherapy andradiotherapy after breast-conserving surgery in early breast cancer Han, S.
 2005
 14 S1 p. S32-
1 p.
 artikel
55 P34 Galectin-9 is a possible prognostic factor withanti-metastatic potential for breast cancer Yamauchi, A.
 2005
 14 S1 p. S25-
1 p.
 artikel
56 P91 Gemcitabine, epirubicin, and docetaxel (GED) asneoadjuvant therapy. Updated results from a multicenter phase II trial in locally advanced breast cancer Yardley, D.
 2005
 14 S1 p. S41-
1 p.
 artikel
57 P26 Gene expression profiles can predict pathologiccomplete response to preoperative chemotherapy with gemcitabine, epirubicin and docetaxel in primary breast cancer Schneeweiss, A.
 2005
 14 S1 p. S21-
1 p.
 artikel
58 P72 Good drug compliance with the oral anticancer drug UFT (Tegafur-Uracil) given as postoperative adjuvant therapy in women with breast cancer Osaki, A.
 2005
 14 S1 p. S36-
1 p.
 artikel
59 P41 High preoperative CA15-3 and CEA concentrationscan predict a poor outcome in breast cancer Park, B.
 2005
 14 S1 p. S27-
1 p.
 artikel
60 P19 Histological diagnosis of lesions of the female breast within 1 hour from core-cut-biopsies — a prospective study to compare breast imaging, rapid embedding and postoperative histological diagnosis Rensing, K.
 2005
 14 S1 p. S19-
1 p.
 artikel
61 P23 Hypermethylation of E-cadherin, GSTP1, 14-3-3σ and TIMP-3 genes as prognostic markers in invasive ductal breast carcinoma Chow, Louis W.C.
 2005
 14 S1 p. S20-
1 p.
 artikel
62 P45 Impact of lymphoid infiltration of tumor on survival ofyoung patients with breast cancer Chobanyan, N.
 2005
 14 S1 p. S28-
1 p.
 artikel
63 P122 Implementation of a Computer Based RapidDiagnostic Breast Clinic Birido, N.
 2005
 14 S1 p. S49-
1 p.
 artikel
64 P71 INC-EU prospective observational Europeanneutropenia study: Design and current status Pettengell, R.
 2005
 14 S1 p. S36-
1 p.
 artikel
65 P83 Incidence of polypharmacy in patients with breastcancer Robertson, J.F.R.
 2005
 14 S1 p. S39-
1 p.
 artikel
66 P13 Induction of redifferentiation of breast cancer as therapeutic target using resveratrol Kim, L.S.
 2005
 14 S1 p. S18-
1 p.
 artikel
67 P2 Intensive Hypermethylation of the CpG Island of Ras Association Domain Family 1A (RASSF1A) in tumour and non-tumorous tissue of breast cancer Yeol, W.
 2005
 14 S1 p. S15-
1 p.
 artikel
68 P64 Intraoperative radiotherapy (IORT) as a boost in patients with early breast cancer Kraus-Tiefenbacher, U.
 2005
 14 S1 p. S32-S33
2 p.
 artikel
69 P57 Ipsilateral breast tumor recurrence afterbreast-conserving therapy: A comparison of quadrantectomy versus lumpectomy in a single institution Noh, W.
 2005
 14 S1 p. S31-
1 p.
 artikel
70 P123 Knowledge and performance of women referringhealth care centers in Kashan towards breast cancer and its screening methods Abedzadeh, M.
 2005
 14 S1 p. S49-
1 p.
 artikel
71 P15 linicopathological features of breast cancer inwomen in different age groups Litwiniuk, M.
 2005
 14 S1 p. S18-
1 p.
 artikel
72 P98 Local Recurrence Rate after Primary Systemic Therapy in Patients with Locally Advanced Breast Cancer Euler, U.
 2005
 14 S1 p. S42-S43
2 p.
 artikel
73 P69 Long term impact on disease-free survival (DFS) andoverall survival (OS) of adjuvant anthracycline (AA) based chemotherapy (CT) in node positive (N+) breast cancer patients (PTS): A report of 258 pts with 20 years (Y) of follow-up (FU) Auvray, H.
 2005
 14 S1 p. S35-
1 p.
 artikel
74 P65 MammoSite Radiation Therapy System (RTS) as theSole Radiation Technique for DCIS of the Breast after Lumpectomy: A Phase II Trial Streeter, J.O.E.
 2005
 14 S1 p. S33-
1 p.
 artikel
75 P86 Neoadjuvant chemotherapy in 710 patients for operable breast cancer: Twenty-two years experience at Centre Jean Perrin Abrial, C.
 2005
 14 S1 p. S39-S40
2 p.
 artikel
76 P88 Neoadjuvant chemotherapy with infusional 5-Fluorouracil, Doxorubicin and cyclophosphamide in locally advanced breast cancer and c-erb-B2 as a prognostic indicator Jeung, H.
 2005
 14 S1 p. S40-
1 p.
 artikel
77 P95 Neoadjuvant Doxorubicin followed sequentially by Cisplatin-Docetaxel in locally advanced breast cancer Ezzat, A.
 2005
 14 S1 p. S42-
1 p.
 artikel
78 P44 NNBC-3 Europe: A prospective clinical trial on riskestimation and optimization of adjuvant chemotherapy in node-negative breast cancer patients Herbst, F.
 2005
 14 S1 p. S28-
1 p.
 artikel
79 P110 Pegfilgrastim (Neulasta®) Enables Delivery of FEC 100 Chemotherapy in Elderly Subjects with High Risk Breast Cancer Romieu, G.
 2005
 14 S1 p. S46-
1 p.
 artikel
80 P36 Persistence of isolated tumor cells (ITC) in bonemarrow (BM) of breast cancer patients predicts increased risk for relapse Janni, W.
 2005
 14 S1 p. S26-
1 p.
 artikel
81 P73 Phase III study evaluating the role of Docetaxel in theadjuvant therapy of breast cancer patients with extensive lymph node involvement (*4 LK+) — Current State of the ADEBAR Study Heinrigs, M.
 2005
 14 S1 p. S36-
1 p.
 artikel
82 P93 Phase II study of epirubicin and docetaxel asneoadjuvant chemotherapy in patients with large breast cancer (stage II-III, tumor size >3.Ocm). Kyushu ET study group in Japan Nishimura, R.
 2005
 14 S1 p. S41-S42
2 p.
 artikel
83 P40 Pooled analysis (n=8,377) validates predictive impactof uPA and PAI-1 for response to adjuvant chemotherapy in breast cancer Harbeck, N.
 2005
 14 S1 p. S27-
1 p.
 artikel
84 P24 Predictive value of p53 and Her-2/neu proteins inpatients with breast cancer Cheshuk, V.
 2005
 14 S1 p. S21-
1 p.
 artikel
85 P49 Predictors of recurrence after breast conservation treatment in 1668 women Parmar, V.
 2005
 14 S1 p. S29-
1 p.
 artikel
86 P78 Prescription behavior in the adjuvant setting of aromatase inhibitors in Germany — final results of a survey among German breast specialists Lueftner, D.
 2005
 14 S1 p. S38-
1 p.
 artikel
87 P35 Prognostic Relevance of Activation of pAkt and pMAPK In Node-Negative Breast Cancer Lee, J.B.
 2005
 14 S1 p. S25-S26
2 p.
 artikel
88 P66 Radiotherapy of early stages of the male breast cancer Hotko, Y.
 2005
 14 S1 p. S33-
1 p.
 artikel
89 P79 Randomized Comparison of Adjuvant Toremifene (Tor) Versus Tamoxifen (Tam) for Postmenopausal Women with Node-Positive (N+), Estrogen Receptor-Positive (ER+) Early Stage Breast Cancer Pagani, O.
 2005
 14 S1 p. S38-
1 p.
 artikel
90 P9 Relations among expression of Ki-67, p53, hormonalreceptors and traditional clinicopathological features in stage I and II breast cancer Dvorak, J.
 2005
 14 S1 p. S17-
1 p.
 artikel
91 P55 Removal of sentinel lymph nodes with the highest and the 2nd highest radioactivity is essential to accurately predict the axillary status Park, B.
 2005
 14 S1 p. S30-
1 p.
 artikel
92 P126 Routes of administration in breast cancer:Preliminary findings from a patient survey Fallowfield, L.
 2005
 14 S1 p. S51-
1 p.
 artikel
93 P128 Safety and tolerability data from the ATAC(‘arimidex’, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment Distler, Wolfgang
 2005
 14 S1 p. S51-
1 p.
 artikel
94 P108 Secondary adjuvant treatment with zoledronate for minimal residual disease in early breast cancer Rack, B.
 2005
 14 S1 p. S45-
1 p.
 artikel
95 P21 Semiquantitative analysis of diffuse pattern of 99mTc-V-DMSA scintimammography in the evaluation of in situ breast carcinomas: A feasible prognostic marker? Papantoniou, V.
 2005
 14 S1 p. S20-
1 p.
 artikel
96 P100 Sentinel lymph node biopsy after neoadjuvantchemotherapy Prado, L.C.B.
 2005
 14 S1 p. S43-
1 p.
 artikel
97 P53 Sentinel lymph node biopsy during prophylactic mastectomy: Is there an indication? Bromberg, S.E.
 2005
 14 S1 p. S30-
1 p.
 artikel
98 P62 Sequencing of regional radiotherapy andchemotherapy does not compromise cytotoxic dose intensity in the ADEBAR-trial Gauge, K.
 2005
 14 S1 p. S32-
1 p.
 artikel
99 P80 Sonographic Appearance of PseudoendometrialChanges in a Patient treated with Anastrozol Luschin, G.
 2005
 14 S1 p. S38-
1 p.
 artikel
100 P6 S-phase of the diploid and aneuploid cell subpopulations in early (pT1) DNA-aneuploid breast cancers Martinez-Arribas, F.
 2005
 14 S1 p. S16-
1 p.
 artikel
101 P48 Surgical treatment of early breast cancer — Moving towards breast conservation and immediate breast reconstruction Tan, E.Y
 2005
 14 S1 p. S29-
1 p.
 artikel
102 P39 Survival of postmenopausal metastatic breast cancerpatients in relation to plasma TGF-betal Nikolic-Vukosavljevic, D.
 2005
 14 S1 p. S26-
1 p.
 artikel
103 P99 Survival over 57 months despite high level ofthrombopenia caused by bone marrow carcinosis of primary metastatic breast cancer Bjelic Radisic, V.
 2005
 14 S1 p. S43-
1 p.
 artikel
104 P82 Tailored chemotherapy trial for women at advancedage with endocrine nonresponsive breast cancer: the CASA Trial Dellapasqua, S.
 2005
 14 S1 p. S39-
1 p.
 artikel
105 P76 Tamoxifen in the early breast cancer treatment.Gynecological aspects Antonova, I.
 2005
 14 S1 p. S37-
1 p.
 artikel
106 P90 Tandem versus single high dose chemotherapy (HDC)with haematopoietic stem cell support in patients with chemosensitive metastatic breast cancer (MBC): outcome parameters - results from a randomised multicenter phase III trial Mohrmann, S.
 2005
 14 S1 p. S40-S41
2 p.
 artikel
107 P14 Tc-99m-(v)dmsa and tc-99m-sestamibiscintimammography in usual type ductal epithelial hyperplasia (uth) and apocrine metaplasia (am) of the breast — does radiotracer uptake relate to ki-67 and er profile and what this indicates about prognosis? Tsiouris, S.
 2005
 14 S1 p. S18-
1 p.
 artikel
108 P114 Ten-year breast cancer survival — At what cost in human and physical terms? A case-control study of long-term survivors of breast cancer and their physical and functional well-being: An updated multivariate analysis Trudeau, M.
 2005
 14 S1 p. S47-
1 p.
 artikel
109 P50 Ten year experience with needle-localized open breastbiopsy for non-palpable breast lesions: BIRADS classification and histopathologic correlation Cericatto, R.
 2005
 14 S1 p. S29-
1 p.
 artikel
110 P70 The ADEBAR-trial — participation in a randomized phase III study (evaluating the role of adjuvant docetaxel in high-risk breast cancer patients) improves treatment strategies and individual patient care in recruiting centers Janni, J.W.
 2005
 14 S1 p. S35-
1 p.
 artikel
111 P42 The age-related ER+PR+ expression differs by HER-2/neu status Huang, H.J.
 2005
 14 S1 p. S27-
1 p.
 artikel
112 P54 The clinical utility of indigo carmine in sentinel lymph node biopsy of the breast cancer Lee, J.B.
 2005
 14 S1 p. S30-
1 p.
 artikel
113 P77 The influence of steroid receptor (SR) content ondisease outcome in early breast cancer patients treated with adjuvant endocrine therapy Susnjar, S.
 2005
 14 S1 p. S37-S38
2 p.
 artikel
114 P52 The intraoperative cytological evaluation of sentinellymph node in patients with breast cancer Prado, L.C.B.
 2005
 14 S1 p. S30-
1 p.
 artikel
115 P112 The methods of the psycho-oncology in optimizationof the primary therapy of the early breast cancer Malova, J.
 2005
 14 S1 p. S46-
1 p.
 artikel
116 P61 The nature of the target in breast conservingradiotherapy using magnetic resonance imaging (MRI) tissue characterisation Whipp, E.
 2005
 14 S1 p. S32-
1 p.
 artikel
117 P121 The perceived care needs of breast cancer patientsin Korea Hwang, S.
 2005
 14 S1 p. S49-
1 p.
 artikel
118 P74 The proportion of women receiving adjuvant systemictherapy for breast cancer and the impact of a protocol adjuvant Neven, P.
 2005
 14 S1 p. S36-S37
2 p.
 artikel
119 P46 Therapeutic results of breast conserving surgery Iwamoto, M.
 2005
 14 S1 p. S28-
1 p.
 artikel
120 P30 The role of HER-2/neu and estrogen receptors in theresponse to tamoxifen and prognosis in women with breast cancer Hegg, R.
 2005
 14 S1 p. S24-
1 p.
 artikel
121 P27 The role of HER-2 overexpression as a predictive factor to neoadjuvant, anthracycline-containing chemotherapy in locally-advanced breast cancer (LABC) Bauer-Kosinska, B.
 2005
 14 S1 p. S21-S24
4 p.
 artikel
122 P97 Treatment of locally advanced breast cancer: Experience at a single Canadian institution Dent, R.
 2005
 14 S1 p. S42-
1 p.
 artikel
123 P125 Treatment of male breast cancer Mudenas, A.
 2005
 14 S1 p. S50-
1 p.
 artikel
124 P25 Use of N-terminal brain natriuretic peptide as a predictive marker for chemotherapy-induced cardiotoxicity Merlini, L.
 2005
 14 S1 p. S21-
1 p.
 artikel
125 P56 Value of axillary dissection technique in combined treatment of Breast Cancer patients Ostapenko, V.
 2005
 14 S1 p. S31-
1 p.
 artikel
126 P130 Weekly paclitaxel — a phase II study in metastaticbreast cancer (BC). Consecutive serum/plasma angiogenic factors in relation to clinical effect Linderholm, B.K.
 2005
 14 S1 p. S51-S52
2 p.
 artikel
127 P103 Zoledronic acid inhibits cancer treatment-induced bone loss in premenopausal patients with breast cancer who are receiving adjuvant endocrine treatment Gnant, M.
 2005
 14 S1 p. S44-
1 p.
 artikel
128 P105 Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer Davidson, N.
 2005
 14 S1 p. S44-
1 p.
 artikel
129 P107 Zoledronic acid is superior to pamidronate in patients with breast cancer and multiple myeloma who are at high risk for skeletal complications Kaminski, M.
 2005
 14 S1 p. S45-
1 p.
 artikel
130 S34 Acceptance of Adjuvant Endocrine Therapies and Quality of Life Issues Fallowfiel, L.
 2005
 14 S1 p. S13-
1 p.
 artikel
131 S27 Adjuvant Chemotherapy for Breast Cancer: One Fit All? Berq, J.
 2005
 14 S1 p. S10-S11
2 p.
 artikel
132 S6 Adjuvant chemotherapy: Standards and beyond Culer, T.
 2005
 14 S1 p. S3-S4
2 p.
 artikel
133 S24 Adjuvant Endocrine Therapies for PostmenopausalWomen: Standards and Not Castiglione-Gertsch, M.
 2005
 14 S1 p. S9-
1 p.
 artikel
134 S23 Adjuvant Endocrine Therapies for Pre/PerimenopausalWomen Pritchard, K.
 2005
 14 S1 p. S9-
1 p.
 artikel
135 S36 Antibodies and Vaccines: Hope or Illusion? Knuth, A.
 2005
 14 S1 p. S13-S14
2 p.
 artikel
136 S15 Biological Variables and Prognosis of DCIS van de Vijve, M.J.
 2005
 14 S1 p. S7-
1 p.
 artikel
137 S1 Breast cancer mortality: Is progress being made? Boyle, P.
 2005
 14 S1 p. S3-
1 p.
 artikel
138 S7 Combination cyclophosphamide — UFT metronomic low-dose chemotherapy for the treatment of metastatic breast cancer: A preclinical analysis Mu oz, R.
 2005
 14 S1 p. S4-S5
2 p.
 artikel
139 S18 DCIS: Which are its Precursors? Boecker, W.
 2005
 14 S1 p. S7-
1 p.
 artikel
140 S25 Do All Patients with Endocrine-Responsive EarlyBreast Cancer Need Adjuvant Chemotherapy before Endocrine Treatment? Albain, Kathy S.
 2005
 14 S1 p. S9-S10
2 p.
 artikel
141 S8 Endocrine Responsiveness: Understanding How Progesterone Receptor Can be Used to Select Endocrine Therapy Osborne, K.
 2005
 14 S1 p. S5-
1 p.
 artikel
142 S37 Endocrine Therapies in the Future: Will an Old Dog Learn New Tricks? Jordan, V.C.
 2005
 14 S1 p. S14-
1 p.
 artikel
143 S5 Endocrine treatment beyond 5 years Goss, P.
 2005
 14 S1 p. S3-
1 p.
 artikel
144 S2 Genetic counseling: Therapeutic consequences Garber, J.
 2005
 14 S1 p. S3-
1 p.
 artikel
145 S12 Histopathology of Primary Breast Cancer 2005 Vial, G.
 2005
 14 S1 p. S6-
1 p.
 artikel
146 S21 Intraoperative Radiation Therapy to the Breast Orecchia, R.
 2005
 14 S1 p. S8-
1 p.
 artikel
147 S4 Letrozole vs. Tamoxifen as adjuvant endocrine therapy for postmenopausal women in receptor-positive breast cancer. BIG 1-98: A prospective randomized double-blind phase III study 2005
 14 S1 p. S3-
1 p.
 artikel
148 S19 Limiting Breast Surgery to the Proper Minimum Morrow, M.
 2005
 14 S1 p. S7-S8
2 p.
 artikel
149 S16 Local and Systemic Treatment of DCIS Manse, R.E.
 2005
 14 S1 p. S7-
1 p.
 artikel
150 S11 New Imaging Beyond Mammography for Women at High Risk for Breast cancer Kuhl, C.
 2005
 14 S1 p. S5-S6
2 p.
 artikel
151 S20 Nipple Sparing Mastectomy in Association with IntraOperative Radiotherapy: A New Type of Mastectomy for Breast Cancer Treatment Petit, J.P.
 2005
 14 S1 p. S8-
1 p.
 artikel
152 S26 Novel Biological Therapeutic Targets Baselga, J.
 2005
 14 S1 p. S10-
1 p.
 artikel
153 S30 Predicting Response to Systemic Treatments:Learning from the Past to Plan for the Future Gelber, R.D.
 2005
 14 S1 p. S11-
1 p.
 artikel
154 S29 Preoperative (Neoadjuvant) Systemic Treatment of Breast Cancer Kaufmann, M.
 2005
 14 S1 p. S11-
1 p.
 artikel
155 S3 Prevention of Cancer: What's new Cuzick, J.
 2005
 14 S1 p. S3-
1 p.
 artikel
156 S13 Prognostic and Predictive Factors Revisited Haves, D.F
 2005
 14 S1 p. S6-
1 p.
 artikel
157 S17 Sentinel Lymphnodes for Localized DCIS? Veronesi, P.
 2005
 14 S1 p. S7-
1 p.
 artikel
158 S33 Special Issues Related to Adjuvant Therapy in ElderlyWomen Muss, H.
 2005
 14 S1 p. S12-S13
2 p.
 artikel
159 S32 Special Issues Related to Adjuvant Therapy in Very Young Women Aebi, S.
 2005
 14 S1 p. S12-
1 p.
 artikel
160 S14 Standards of Follow-Up for Primary Breast Cancer Wine, E.P.
 2005
 14 S1 p. S6-S7
2 p.
 artikel
161 S28 The Best Use of Adjuvant Chemotherapy: New Drugs and New Use of “Old” Drugs Hudis, C.
 2005
 14 S1 p. S11-
1 p.
 artikel
162 S10 The Biology of BRCA 1/2 and Beyond Borq, A.
 2005
 14 S1 p. S5-
1 p.
 artikel
163 S9 The Biology of Steroid Hormones and Endocrine Therapies Dowsett, M.
 2005
 14 S1 p. S5-
1 p.
 artikel
164 S31 Toward a More Rational Selection of Tailored AdjuvantTherapy: Data from the National Surgical Adjuvant Breast and Bowel Project Bryan, J.
 2005
 14 S1 p. S12-
1 p.
 artikel
165 S38 When to Recommend and to Pay for AdjuvantTreatment of Breast Cancer? Porzsolt, F.
 2005
 14 S1 p. S14-
1 p.
 artikel
166 S35 When Will More Useful Predictive Factors Be Readyfor Use? Mauriac, L.
 2005
 14 S1 p. S13-
1 p.
 artikel
167 S22 Which extent of Adjuvant Radiotherapy is Standard? Bellon, J.
 2005
 14 S1 p. S8-S9
2 p.
 artikel
                             167 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland